Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals (Nasdaq: ETON) announced Judith M. Matthews will become Chief Financial Officer effective June 1, 2026.

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) announced Judith M. Matthews will become Chief Financial Officer effective June 1, 2026. Matthews brings more than 25 years of finance leadership in pharma and biotech. Current CFO James Gruber will remain through May 31, 2026 and then enter a six-month consulting agreement.

Positive

• Experienced hire: Judith Matthews brings >25 years of finance leadership in pharma and biotech
• Planned transition: incumbent CFO remains through May 31, 2026 to ensure continuity
• Consulting support: outgoing CFO will provide six months of consulting after stepping down

Negative

• None.

Argus Apr 16 session

-9.42% close to close Open Argus

Details

News Market Reaction – ETON

In the Apr 16 session, ETON declined 9.42%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.4% in the session following this news. A negative reaction despite a planned CFO ...

Analysis

The stock moved -9.4% in the session following this news. A negative reaction despite a planned CFO transition would fit a pattern where some positive events, such as the DESMODA approval on Feb 25, 2026, were followed by short-term weakness. Markets sometimes treat leadership changes as an opportunity to lock in gains, especially with the stock trading near a 52-week high. While the transition appears orderly, any concern about execution, financing flexibility, or integration of new products could amplify downside pressure until management provides further clarity.

Key Figures

CFO effective date: June 1, 2026 Current CFO transition end: May 31, 2026 Consulting period: 6 months +2 more

CFO effective date

June 1, 2026

Judith M. Matthews to assume Chief Financial Officer role

Current CFO transition end

May 31, 2026

James Gruber remains CFO through this date

Consulting period

6 months

James Gruber to enter six-month consulting agreement with Eton

Finance leadership experience

More than 25 years

Judy Matthews’ finance leadership background in pharma and biotech

Iterum CFO tenure

2015–2026

Served as Chief Financial Officer of Iterum Therapeutics plc

Historical Context

5 past events · Latest: Mar 19

5 events

1. Mar 19

   Earnings results

   24h Move

   +7.5%

   Reported strong Q4 and 2025 results with major revenue and EBITDA growth.

2. Mar 03

   Earnings call date

   24h Move

   +0.5%

   Announced timing of Q4 and full-year 2025 earnings call and webcast.

3. Mar 02

   Portfolio acquisition

   24h Move

   +6.8%

   Acquired U.S. rights to HEMANGEOL, expected to be accretive to 2026 earnings.

4. Feb 25

   FDA approval

   24h Move

   -3.5%

   Received U.S. FDA approval for DESMODA oral solution for diabetes insipidus.

5. Feb 20

   Conference participation

   24h Move

   -1.6%

   Announced leadership participation in Leerink Partners Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st

DEER PARK, Ill., April 16, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the appointment of Judith “Judy” M. Matthews as Executive Vice President, Accounting and Finance. Ms. Matthews will assume the role of Chief Financial Officer effective June 1, 2026.

The Company’s current Chief Financial Officer, James Gruber, will then step down as part of a planned succession. To ensure a seamless transition, Mr. Gruber will remain in his role through May 31, 2026, and will subsequently enter into a six-month consulting agreement with Eton.

“We are pleased to welcome Judy to Eton. She brings deep experience leading finance for growth-focused pharmaceutical companies and will be a valuable addition as we enter our next phase of growth,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “On behalf of the entire Company, I want to thank James for his contributions and dedication over the last four years. He provided exceptional leadership to our finance department through a period of rapid growth and numerous product integrations.”

“Eton’s unique model and impressive execution have set it apart in the industry. I am excited to be joining the organization at such a pivotal time, and I look forward to partnering with the team on the mission to build the largest rare disease portfolio in the United States,” said Judy Matthews, Executive Vice President, Accounting and Finance.

Ms. Matthews brings more than 25 years of finance leadership experience, including significant experience at fast-growing pharmaceutical and biotechnology companies. Prior to joining Eton, she served as Chief Financial Officer of Iterum Therapeutics plc from 2015 to 2026. Previously, she was Vice President of Finance at Durata Therapeutics until its acquisition by Actavis plc.

Ms. Matthews holds a B.A. in Accounting from the University of Illinois at Urbana-Champaign and a Master of Management in Finance and Marketing from the Kellogg School of Management at Northwestern University.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI^TM, INCRELEX^®, ALKINDI SPRINKLE^®, DESMODA™, GALZIN^®, HEMANGEOL^®, PKU GOLIKE^®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia^®, ET-700, ET-800 and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who will be ETON's new CFO and when does Judith Matthews assume the role?

Judith M. Matthews will become ETON's Chief Financial Officer effective June 1, 2026. According to the company, Matthews joins as Executive Vice President, Accounting and Finance and will transition into the CFO role on that date.

What is Judith Matthews' finance and industry experience prior to joining ETON (ETON)?

Matthews has over 25 years of finance leadership, including CFO of Iterum Therapeutics from 2015–2026. According to the company, she also served in senior finance roles at Durata Therapeutics before its acquisition.

How will ETON manage the CFO transition and ensure continuity through June 2026?

Eton says the current CFO, James Gruber, will remain in his role through May 31, 2026. According to the company, Gruber will then provide continuity via a six-month consulting agreement after stepping down.

What education credentials does ETON's incoming CFO Judith Matthews hold?

Judith Matthews holds a B.A. in Accounting from the University of Illinois Urbana-Champaign and a Master of Management in Finance and Marketing from Kellogg School of Management, per the company.

Will the CFO change at ETON affect the company's leadership stability in 2026?

The company frames the move as a planned succession with overlap to support stability. According to Eton, the outgoing CFO stays through May 31, 2026 and will consult for six months to aid the transition.